Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQNDdBQWp0eXhySGlJdTloSFcwMVk1WmY1NzVlZldsRDZRTjRRdy0zTHVCbXU5QjRlSWdFWmI2OGNXNmN6SHp2dF9oOEItN1E2dl9kSnZjZVYwT096T1V0aUpvT0pzX29aWVhILVBLMDdZMkRQX2VsZHBrRUJuT3phY1MzQ2Rlcy12OEZWTm9XWG12YmZDVkI1cU1ObWtzNzJOcEN1MklZZ2dQWWxMRGJMQThLZFdFZw?oc=5" target="_blank">Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PMNovartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026 at 10:57 AMHormel Foods to buy Brakebush in deal valued at $1.06 billion - Reuters
Hormel Foods to buy Brakebush in deal valued at $1.06 billion Reuters
September 30, 2026 at 10:49 AM